However, adjustment for BrCa SERM treatment only somewhat attenuated the still significantly elevated per-year aOR among cases, suggesting that treatment only partially accounted for the VMS increase in contrast to findings from prior studies of BrCa cases taking aromatase inhibitors [6, 7] or tamoxifen [8]. Here, CYP19A1 is linked to invasive breast carcinoma.